Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
13(72.2%)
Early Phase 1
5(27.8%)
18Total
Phase 1(13)
Early Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT03829540Phase 1Recruiting

CD4CAR for CD4+ Leukemia and Lymphoma

Role: collaborator

NCT07544160Phase 1Not Yet Recruiting

BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)

Role: lead

NCT06071624Phase 1Recruiting

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Role: collaborator

NCT06197672Phase 1Recruiting

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Role: collaborator

NCT07328581Phase 1Not Yet Recruiting

BCMA-CD19 cCAR T for the Treatment of Refractory Lupus

Role: lead

NCT04162353Phase 1Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Role: lead

NCT06787989Phase 1Recruiting

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Role: lead

NCT05474885Phase 1Unknown

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Role: lead

NCT05445765Phase 1Unknown

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Role: lead

NCT05212584Phase 1Unknown

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Role: lead

NCT04934774Phase 1Unknown

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Role: lead

NCT04162340Phase 1Unknown

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Role: lead

NCT03795779Early Phase 1Unknown

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Role: lead

NCT04594135Phase 1Unknown

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Role: lead

NCT04156243Early Phase 1Unknown

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Role: lead

NCT04156178Early Phase 1Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Role: lead

NCT04156256Early Phase 1Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Role: lead

NCT04156269Early Phase 1Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Role: lead

All 18 trials loaded